Accelerating Children's HIV/AIDS Treatment (ACT) Initiative

December 1, 2014

Date: 08/14/2014 Description: Photo courtesy of The Elizabeth Glaser Pediatric AIDS Foundation © EGPAF Photo

The Accelerating Children’s HIV/AIDS Treatment (ACT) Initiative is a two-year effort to double the number of children receiving life-saving antiretroviral treatment (ART) in sub-Saharan Africa.  The $200 million initiative will enable 300,000 more children living with HIV to receive ART and is funded by the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) and the Children’s Investment Fund Foundation (CIFF).

Cameroon, Democratic Republic of Congo, Kenya, Lesotho, Malawi, Mozambique, Tanzania, Zambia, and Zimbabwe have been selected to participate in ACT.  PEPFAR and CIFF worked together to select the participating countries, which are among those with the lowest access to pediatric treatment, and the greatest disparity in treatment coverage for children compared to adults living with HIV/AIDS.  Ensuring that children are healthy and live to adulthood enables them to grow economies, create jobs, and contribute to their families and communities for decades to come. ACT was launched during the U.S.-Africa Leaders Summit in August 2014. Fact Sheet» PEPFAR Press Release» White House Press Release»

Accelerating Innovation with Global Pediatric Antiretroviral Commitment-to-Action

While 3.2 million children are living with HIV/AIDS today, only one fourth has access to treatment. The Global Pediatric Antiretroviral (ARV) Commitment-to-Action brings together leading organizations to accelerate the development of new high-priority pediatric ARV co-formulations for first- and second-line treatment by 2017. PEPFAR, the Pediatric HIV Treatment Initiative (a collaboration of UNITAID, Clinton Health Access Initiative, Drugs for Neglected Diseases initiative, and Medicines Patent Pool), and the Global Fund to Fight AIDS, Tuberculosis and Malaria will work together on this Commitment-to-Action. Greater access to HIV medicines will reduce illness and death, particularly among the youngest and most vulnerable children living with HIV/AIDS. To further advance the effort, PEPFAR is contributing $2 million through the U.S. Food and Drug Administration to support their work on regulatory systems in Africa, ensuring that quality and safety products (drugs and diagnostic tests) are rapidly approved by national regulatory agencies – this includes new pediatric ARV formulations. Press release» Fact Sheet»


Share the Facts

  • Funds from @PEPFAR & @CIFFchild will double the # of children receiving #HIV treatment across 10 #African countries 
  • Funds from @PEPFAR and @CIFFchild will provide treatment to least 300,000 more children living w #HIV in nxt 2yrs #AIDSFreeGen 
  • #FACT: Without treatment, 1/2 of children living with #HIV die before their 2nd birthday & 80% before they are five.
  • Thru #ACT PEPFAR-@CIFFchild partnership will jointly invest $200 mill: $150 mill frm PEPFAR &up to $50 mill frm CIFF